We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Werfen Completes Immucor Acquisition to Expand Leadership in Specialized Diagnostics

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Werfen had reached an agreement in November 2022 to acquire Immucor for USD 2 billion (Photo courtesy of Werfen)
Image: Werfen had reached an agreement in November 2022 to acquire Immucor for USD 2 billion (Photo courtesy of Werfen)

Werfen (Barcelona, Spain) has successfully completed the acquisition of Immucor, Inc. (Norcross, GA, USA) after receiving the required regulatory and antitrust approvals. In November 2022, Werfen reached an agreement to acquire Immucor, a privately held in vitro diagnostics (IVD) company with a strong presence in the global Transfusion and Transplant markets, for approximately USD 2 billion. The Transfusion and Transplant product lines complement Werfen's existing Hemostasis, Acute Care, and Autoimmunity business lines, expanding its portfolio of Specialized Diagnostic solutions for hospitals and clinical laboratories.

With the integration of Immucor, Werfen has expanded its presence as a company of reference in the Specialized Diagnostics market and grown its portfolio of diagnostic solutions for hospitals and clinical laboratories. Additionally, Werfen will have seven technology centers and employ more than 7,000 people worldwide; with a direct presence in over 30 countries and across more than 100 territories through distributors.

"During our more than 50-year history, we have demonstrated our strong commitment to expand our IVD business through organic growth, complemented with highly strategic acquisitions," said Carlos Pascual, CEO of Werfen.

Related Links:
Werfen 
Immucor, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.